NCT03267251: EPICC-HPV

Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV)

Withdrawn NA Last updated 12 July 2023

What this trial tests

NA trial testing Vacteens Web app for mobile devices in Vaccine Decision Making. Withdrawn.

Timeline

28 August 2017

Primary endpoint
28 August 2017

28 August 2017

Quick facts

Lead sponsor	University of New Mexico
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Start date	28 August 2017
Primary completion	28 August 2017
Estimated completion	28 August 2017

Drugs / interventions tested

• Vacteens Web app for mobile devices
• Standard Usual and Customary HPV Information - CDC pamphlet

Conditions studied

• Vaccine Decision Making — all drugs for Vaccine Decision Making →

Sponsor

University of New Mexico

Who can join

26 and older, any sex, with Vaccine Decision Making. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vaccination against Human Papillomavirus is recommended for adolescent females by the Advisory Committee on Immunization Practices (ACIP), physicians, and many medical organizations, yet uptake of HPV vaccines remains very low. CDC data reveal that in 2013 only 44.3% of 13-17 year old females in New Mexico (and 37.6% nationwide) had completed the 3-dose HPV vaccine series. These data reveal the uptake of the HPV vaccines is unacceptably low, thereby diminishing its ability to provide population-level protection against the HPV types known to cause cervical, vaginal, and vulvar cancers in women, oropharyngeal and anal cancers in men and women, and penile cancers in men. The danger of very low vaccination rates is that adolescents of all ages will continue to be vulnerable to HPV and the associated cancer risks.

Despite recommendations for HPV, parents continue to have concerns about HPV vaccination. Clinicians often lack a clear frame for discussions about HPV vaccination with parents, so much so that recent research indicates that pediatricians' discussions with parents about vaccinations in general often take the form of bargaining, e.g., "since this may be too early for the vaccination, can we delay the vaccination schedule?" Effective messaging is needed to close a knowledge gap among parents around HPV and HPV vaccines, improve communication and shared decision-making about HPV vaccination between adolescent girls' parents and physicians, and ultimately prompt uptake of HPV vaccines.

This project will employ a web-based intervention on HPV as a way to improve knowledge, communication and shared decision-making about HPV vaccination for 11-13 year old girls and their parents. A clinic-based comparative effectiveness randomized trial will be used to examine the impact of the website on vaccine-related outcomes and vaccine uptake. New Mexico pediatric clinics will be randomly assigned to either the usual care clinic-based communication about HPV vaccination or to usual care plus web-based dissemination. Assessments of vaccine-related outcomes, including shared decision-making between girls, parents and physicians, will be assessed at baseline, 3 months, and 9 months and vaccine uptake and dose adherence will be abstracted from clinic vaccine records at 9 months. An effective web-based resource should increase parents' knowledge, intentions and motivations to vaccinate

Publications & conference data

No peer-reviewed publications indexed yet for this trial.